Steiner Loïc, Eldh Maria, Offens Annemarijn, Veerman Rosanne E, Johansson Markus, Hemdan Tammer, Netterling Hans, Huge Ylva, Abdul-Sattar Aljabery Firas, Alamdari Farhood, Lidén Oskar, Sherif Amir, Gabrielsson Susanne
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
Department of Diagnostics and Intervention, Umeå University, Umeå, Sweden; Department of Surgery, Urology Section, Sundsvall-Härnösand Hospital, Sundsvall, Sweden.
Cancer Lett. 2025 Jan 28;609:217352. doi: 10.1016/j.canlet.2024.217352. Epub 2024 Nov 23.
Urinary Bladder Cancer (UBC) ranks among the most prevalent cancers worldwide, has a high recurrence rate and unpredictable treatment responses. Thus, biomarkers are urgently needed. Extracellular vesicles (EVs) are released from both cancer- and immune cells and provide a snapshot of the originating cell. They are abundant in urine and are therefore candidate biomarkers for UBC. Isolated urinary EVs from 39 UBC patients were compared with EVs from healthy controls, prostate cancer patients and whole urine. Samples were from bladder urine at time of both transurethral resection of the bladder tumour (TURB) and cystectomy, as well as urine taken from the ureter at cystectomy. EVs were isolated by tangential flow filtration and differential ultracentrifugation and their protein composition was detected by Proximity Extension Assay (PEA; Olink, immuno-oncology panel). In UBC patients, the proteomic signature of bladder urine EVs differed from ureter urine EVs from the same individuals, and from bladder urine derived EVs of both healthy and prostate cancer controls. Pairwise comparison was performed with matched whole urine revealing proteins solely detected in isolated vesicles. Additionally, a distinct signature was identified in bladder urine EVs correlating with muscle invasiveness, and a trained classifier could predict UBC with 92 % accuracy. Some differentially expressed proteins, HO-1 and MMP7, were analysed by bead-based flow cytometry, where HO-1 was detected on the EV surface. Taken together, these results strengthen the rationale of using EVs as non-invasive biomarkers and prognostic tools for UBC.
膀胱癌(UBC)是全球最常见的癌症之一,具有高复发率和不可预测的治疗反应。因此,迫切需要生物标志物。细胞外囊泡(EVs)由癌细胞和免疫细胞释放,反映了来源细胞的情况。它们在尿液中含量丰富,因此是UBC的候选生物标志物。将39例UBC患者分离出的尿液EVs与健康对照、前列腺癌患者的EVs以及全尿进行比较。样本来自膀胱肿瘤经尿道切除术(TURB)和膀胱切除术时的膀胱尿液,以及膀胱切除术时从输尿管采集的尿液。通过切向流过滤和差速超速离心分离EVs,并采用邻位延伸分析(PEA;Olink,免疫肿瘤学面板)检测其蛋白质组成。在UBC患者中,膀胱尿液EVs的蛋白质组特征与同一患者输尿管尿液EVs不同,也与健康对照和前列腺癌对照的膀胱尿液来源的EVs不同。与匹配的全尿进行成对比较,发现了仅在分离的囊泡中检测到的蛋白质。此外,在膀胱尿液EVs中鉴定出与肌肉浸润相关的独特特征,并且经过训练的分类器可以以92%的准确率预测UBC。通过基于磁珠的流式细胞术分析了一些差异表达的蛋白质,如HO-1和MMP7,其中在EV表面检测到了HO-1。综上所述,这些结果强化了将EVs用作UBC的非侵入性生物标志物和预后工具的理论依据。